HPV vaccination against cervical cancer in women above 25.pdfVIP

Gynecologic Oncology 115 (2009) S15–S23 Contents lists available at ScienceDirect Gynecologic Oncology journal homepage: www. elsevier. com/ locate/ ygyn o HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives Xavier Castellsagué a,⁎, Achim Schneider b, Andreas M. Kaufmann b, F. Xavier Bosch a a Cancer Epidemiology Research Program, Institut Català dOncologia, IDIBELL, CIBER-ESP, Barcelona, Spain b Charité Universitätsmedizin Berlin, Berlin, Germany a r t i c l e i n f o a b s t r a c t Article history: Objective. Vaccination of young women (15–25 years of age) against human papillomavirus (HPV) has Received 10 July 2009 been shown to be very efficacious in preventing the development of moderate or severe cervical precancerous lesions associated with HPV-16 or -18. As the highest rates of new infections with high-risk Keywords: (i.e., oncogenic) HPV types occur in the first years following sexual debut, most existing guidelines and Human papillomavirus recommendations advise on vaccinating young girls. We consider oncogenic HPV infection and the risk of Prophylactic vaccination developing cervical cancer in women over 25 years of age and whether they would also benefit from Women of all ages HPV risk vaccination against HPV.